Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Apoferritin-Based Nanocapsules Used to Transport Toxic Anticancer Drug

By LabMedica International staff writers
Posted on 08 Nov 2015
A toxic anticancer therapeutic agent was encapsulated in capsules derived from apoferritin, which sequestered the drug until its selective delivery to cancer cells.

Ferritin is a globular protein complex consisting of 24 protein subunits and is the primary intracellular iron-storage protein in both prokaryotes and eukaryotes, keeping iron in a soluble and non-toxic form. More...
Ferritin that is not combined with iron is called apoferritin.

Investigators at Washington State University (Pullman, USA) were looking for a better way to administer the anticancer drug daunorubicin. This drug interacts with DNA by intercalation and inhibition of macromolecular biosynthesis. This inhibits the progression of the enzyme topoisomerase II, which relaxes supercoils in DNA for transcription. Daunorubicin stabilizes the topoisomerase II complex after it has broken the DNA chain for replication, preventing the DNA double helix from being resealed and thereby stopping the process of replication. The drug is administered via rapid intravenous infusion. It cannot be given intramuscularly or subcutaneously, since it may cause extensive tissue necrosis. If administered into the spinal canal, it will cause extensive damage to the nervous system and may lead to death.

To circumvent daunorubicin's toxic properties the investigators loaded a mixture of the hydrophobic drug and hydrophilic poly-L-aspartic acid (PLAA) into molecules of apoferritin under slightly acidic conditions that caused the apoferritin molecules to swell. Back at normal pH, the surface of the drug-carrying apoferritin capsules was modified with hyaluronic acid (HA), which targeted the capsules to the cancer cells' to the HA-receptor CD44.

The drug-bearing capsules were used to treat cultures of human embryonic lung MRC-5 cells and lung cancer A549 cells. Results published in the October 2015 issue of the journal Biomaterials Science revealed that the drug was maintained within the capsules until delivery and subsequent uptake by the cancer cells. Release of the drug by the acidic environment of the cancer cells resulted in death of more than 70% of them with no damage to normal cells.

"Our efficiency in killing the cancer cell was very high with no toxicity to normal cells,'' said senior author Dr. Yuehe Lin, professor of mechanical and materials engineering at Washington State University. "At the cell level, we were able to demonstrate it was very effective.''

Related Links:

Washington State University



Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.